Document:

tronbiontechmymutntransf

Seite 1/2 Bankverbindung: Mainzer Volksbank eG, IBAN: [***], BIC: [***] Amtsgericht Mainz: HRB 43191 - USt.-Id.Nr.: DE 269156552 [***] TRON gGmbH, Freiligrathstraße 12, D-55131 Mainz TRON gGmbH Freiligrathstraße 12 D - 55131 Mainz [***] [***] [***] [***] [***] 10.09.2021 BioNTech SE An der Goldgrube 12 55131 Mainz Transfer of Source Code for MyMUT® Software Version [***] TRON gGmbH is currently developing MyMut Software Version [***] and intends to successively transfer the  full source code of the MyMUT® software version [***] latest by October 15th, 2021 under the URL [***],  encrypted zip archive; the key will be sent separately as a printout) to BioNTech. With regard to the use of the  data and the software by BioNTech SE, TRON recognizes that the software will be used for the so-called IVAC  project. Since the IVAC Supplementary Agreement dated January 1st 2015 between TRON and BioNTech expired on  December 31st 2019 and no other related agreement between BioNTech SE and TRON gGmbH has been  concluded so far, TRON hereby transfer these data (including inventions, rights to patent applications /  patents and so-called trade secrets) subject to the rights of use to which TRON, TRON AFFILIATED  COMPANIES and the respective cooperation partners are entitled in the IVAC Supplementary Agreement with  the proviso that Sec. 6.4.1. of the Framework Collaboration Agreement ( "WP5") between BioNTech SE and  TRON gGmbH is applied as amended in Schedule 1, which amendment shall be effective solely for the  purpose of this letter and the exploitation of the SOURCE CODE including any so called trade secret inventions  contained in the SOURCE CODE . All other terms of the IVAC Supplementary Agreement shall remain  unaffected. The parties further agree, via separate amendment, to extend the term of the IVAC Supplemental  Agreement to Dec. 31st 2023.  BioNTech SE accepts transfer under this letter agreement and recognizes the fulfillment of the obligations by  TRON according to the IVAC Supplementary Agreement with regard to the above data. Mainz, ......................................................... Mainz, ........................................................... /s/ Michael Föhlings      /s/ Dr. Andrée Rothermel ..............................................................................         /s/ Sierk Poetting ................................................................... Michael Föhlings        Dr. Andrée Rothermel Sierk Poetting Managing Director     Managing Director COO, Managing Director BioNTech 8 TRON  1 oocuSigned by:  L~ [ DocuSigned by:  >~  E78E248002F342F ...  • TRON - Translationale Onkolog ie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH       -  Translati al  Onkologie an der  U i i ä i  der  Johan   t r - tä  ainz ge i ü     THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN  EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE  COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 4.61 

 

Seite 2/2 Bankverbindung: Mainzer Volksbank eG, IBAN: [***]41, BIC: [***] Amtsgericht Mainz: HRB 43191 - USt.-Id.Nr.: DE 269156552 [***] Schedule 1 Amendment to Sec. 6.4.1. of the Framework Collaboration Agreement ( "WP5") This Amendment is agreed by the PARTIES for the sole purpose of regulating the remuneration payable  by the relevant BIONTECH PARTY to TRON for the exploitation of a TRADE SECRET INVENTION  to the extent any such TRADE SECRET INVENTION is part of the source code of the MyMUT®  software version N under the URL [***], encrypted zip archive; the key will be sent separately as a  printout) (the “SOURCE CODE”). For this purpose only, Sec. 6.4.1 of the Framework Collaboration  Agreement (“WP5”) will read as follows: “For the WP5 CONTRACTUAL PRODUCTS sold by it or its licensees (or sublicensees) to THIRD  PARTIES which fall within the scope of protection of a VALID CLAIM of a WP5 PROJECT PATENT  or a TRADE SECRET INVENTION, the BIONTECH PARTY shall pay TRON remuneration to the  amount of (i) [***] percent ([***]) of the WP5 CONTRACTUAL PRODUCT's NET SELLING PRICE  up to an annual aggregate worldwide NET SELLING PRICE per WP5 CONTRACTUAL  PRODUCT of [***] euro (€[***]); and (ii) [***] percent ([***]) of the WP5 CONTRACTUAL PRODUCT's NET SELLING  PRICE if the annual aggregate worldwide NET SELLING PRICE per WP5 CONTRACTUAL  PRODUCT exceeds [***] euro ([***]). The aforementioned remuneration under this clause 6.4.1 shall be paid on a country-by-country basis for  so long as the relevant WP5 CONTRACTUAL PRODUCT is covered by a VALID CLAIM of a WP5  PROJECT PATENT in the country of sale. If a WP5 CONTRACTUAL PRODUCT falls within the  scope of a TRADE SECRET INVENTION, it is the mutual expectation of the PARTIES that the exploitation of such TRADE SECRET INVENTION will be coherent and jointly together with the  exploitation of one or more WP5 PROJECT PATENTS. Based on that understanding, the royalty pursuant to this clause 6.4.1 for the use of a TRADE SECRET  INVENTION shall only be payable (x) if the relevant WP5 CONTRACTUAL PRODUCT also falls  within the scope of protection of a VALID CLAIM of a WP5 PROJECT PATENT or, (y) in the event  that the BIONTECH PARTY should exploit a TRADE SECRET INVENTION by entering into an  agreement with a THIRD PARTY, if the relevant WP5 CONTRACTUAL PRODUCT also falls within  the scope of protection of a VALID CLAIM of a patent ( co )owned by such THIRD PARTY ("THIRD PARTY PATENT").  The royalty is payable, on a WP5 CONTRACTUAL PRODUCT-by- WP5 CONTRACTUAL  PRODUCT basis, only once per WP5 CONTRACTUAL PRODUCT, even if a WP5 CONTRACTUAL PRODUCT falls within the scope of protection of several WP5 PROJECT PATENTS and/or TRADE  SECRET INVENTIONS.” For the avoidance of doubt, the sentence in Sec. 6.4.1. of the Framework Collaboration Agreement  "WP5") starting “If such exploitation is undertaken.....” shall be deleted in its entirety.  For all other purposes the original version of Sec. 6.4.1 shall remain unchanged, in full effect and shall  not be affected by the aforementioned amendment. 9 TRON  • TRON - Translationale Onkolog ie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH       -  Translati al  Onkologie an der  U i i ä i  der  Johan   t r - tä  ainz ge i ügenmabamendmenttoletter_

Execution Version   1 of 5  Amendment to Letter Agreement of November 11, 2020 in relation to Genmab’s  proprietary [***]  This Amendment Agreement to the Letter Agreement of November 11, 2020 (the Letter  Agreement Amendment) is entered into as of 15 December 2021 by and between   BioNTech SE, a German corporation having its principal office at An der Goldgrube  12, 55131 Mainz, Germany (Biontech)  and   Genmab A/S, CVR no. 21023884, a Danish corporation having its principal office at  Bredgade 34E, P.O. Box 9068, DK-1260 Copenhagen K, Denmark, (Genmab).  (Biontech and Genmab each a Party and together the Parties)  PREAMBLE  WHEREAS, as of 11 November 2020, the Parties have concluded a letter agreement  (the Letter Agreement, as amended from time to time) relating to the potential  expansion of the License and Collaboration Agreement concluded by the Parties as of  19 May 2015 (the Collaboration Agreement),  WHEREAS the Letter Agreement has been extended by the Parties several times and  will currently expire on 15 December 2021.  WHEREAS, under the Letter Agreement, the Parties are negotiating an amendment to  the Collaboration Agreement to expand the terms of the Collaboration Agreement to  include Genmab’s proprietary [***]. The current status of such negotiation is  reflected in (i) the draft Amendment version sent by Genmab to Biontech on [***]  attached to this Letter Agreement Amendment as Appendix 1 and (ii) the issues list  produced by Biontech in response to such version attached to this Letter Agreement  Amendment as Appendix 2. WHEREAS, the Parties have decided to no longer pursue their collaboration in relation  to the [***] product under an amendment to the Collaboration Agreement, but to  establish a separate agreement for such purpose (the [***] Agreement).  WHEREAS, the Parties intend to negotiate and execute such [***] Agreement  as quickly as possible, but in any event no later than [***].   WHEREAS, until the [***] Agreement has been executed, the Parties wish to continue  their development of the [***] product pursuant to the terms of the Letter Agreement,  as amended by this Letter Agreement Amendment.   NOW, THEREFORE, the Parties hereby agree as follows:  THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN  EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE  COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 4.66 

 

2 of 5  1. NEGOTIATION OF [***] AGREEMENT 1.1  1.2  The Parties agree to negotiate in good faith the [***] Agreement to govern  their collaboration in relation to the development of Genmab’s  proprietary [***] antibody with the goal to execute such  agreement as early as possible, but in any event no later than [***].  The [***] Agreement shall be based on:  (i) [***] and (ii) [***], and (iii) [***]. 1.3 Biontech will prepare a draft amended and restated Collaboration  Agreement and on that basis subsequently a first draft of the [***]  Agreement and provide such drafts to Genmab for review as soon as  reasonably possible.  2. AMENDMENTS TO LETTER AGREEMENT 2.1  2.2  The Parties agree to extend the “Expiry Date” under Letter Agreement  until [***].  In the event that, prior to the Expiry Date or to the execution of  the [***] Agreement, (i) the Joint Steering Committee mutually  decides to discontinue the Development of the [***] product and/or (ii)  a Regulatory Authority suspends the Clinical Study referred to by the  Parties as [***] for the [***] product  due to product safety or quality issues  and such Clinical Study is not allowed to resume prior to the Expiry Date  or execution of the [***] Agreement, the following shall apply, unless  otherwise agreed in writing:  (a) The Parties shall share all costs for the Development of the [***] product as per the then current Development Plan and Budget to the  extent such costs have been incurred or committed to by the Parties  during the Negotiation Period, and in accordance with the principles set  out in Section 7.3 to 7.11 of the Collaboration Agreement. Following  an event described in this Section 2.2, romanette (i) and (ii) above,  Genmab and Biontech will each invoice the other party for the costs to  be shared in accordance with the principles set out in Section 7.6 of the  Collaboration Agreement. 

 

3 of 5 (b) The Parties shall work together to ensure that any ongoing activities  related to the [***] product are properly wound down, and shall share  costs related to such winding down, if any; and (c) Neither Party shall have the right to continue Development,  Manufacturing or Commercialization of the [***] product without  prior written agreement between the Parties. 3. OTHER 3.1 Capitalized terms used in this Letter Agreement Amendment that are not  defined in it shall have the meanings given to them in the Letter Agreement,  or, to the extent such capitalized terms are not defined in the Letter  Agreement, the meanings given to them in the Agreement. 3.2 Save as set forth in this Letter Agreement Amendment, all other terms and  conditions of the Letter Agreement shall remain in full force and effect. 3.3 The Parties agree that this Letter Agreement Amendment may be signed using  DocuSign® electronic signature. Such electronic signature is the legally  binding equivalent to a Party’s handwritten signature and it has the same  validity, enforceability and meaning as a handwritten signature and the  Parties hereby waive any objection to the contrary. For Genmab A/S: Anthony Mancini Executive Vice President & Chief Operating Officer For Biontech SE: Dr. Sierk Pötting Managing Director Appendices: Appendix 1 - Appendix 2 – Draft Version of Amendment No 7 to the Collaboration Agreement  as provided by Genmab on [***] (with redlines by Genmab) Open Issues List as provided by Biontech on [***] ( DocuSigned by:  I ~,,,,~  l(J Signer Name: Anthony Mancini  L Signing Reason: I approve this document  Signing Time: 21-Dec-2021 14:08:47 PM CET  FABF189664EE4D6FBC46253B5EAE43B9  ( DocuSigned by:  I 5:/?  l(J Signer Name: Sierk Poetting  L Signing Reason: I approve this document  Signing Time: 22-Dec-2021 I 9:46:33 AM PST  E78E248002F342FE8B B3F933080F88A5  [***] [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]